menu
    • menu
    [{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"GP2 Peptide","moa":"HER2\/Neu protein","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intradermal injection","sponsorNew":"Greenwich LifeSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Undisclosed"},{"orgOrder":0,"company":"Westport Bio","sponsor":"Greenwich LifeSciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"GP2 Peptide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Westport Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Westport Bio \/ Greenwich LifeSciences","highestDevelopmentStatusID":"4","companyTruncated":"Westport Bio \/ Greenwich LifeSciences"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Not Applicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Not Applicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Not Applicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Not Applicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Not Applicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Not Applicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Not Applicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"GP2 Peptide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Greenwich LifeSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Undisclosed"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Greenwich LifeSciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for GP2 Peptide

    Menu

    GP2 Peptide

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP2 Peptide,GM-CSF

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

                            Details : GLSI-100 (GP2 + GM-CSF) is a peptide of the HER2/neu protein delivered in combination with GM-CSF. It is being evaluated for HER2/neu positive breast cancer.

                            Brand Name : GLSI-100

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            August 01, 2024

                            Lead Product(s) : GP2 Peptide,GM-CSF

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP2 Peptide,GM-CSF

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $2.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Greenwich LifeSciences Announces $2.5 Million Private Placement

                            Details : The net proceeds will be used to fund the clinical advancement of the GLSI-100 (GP2 + GM-CSF) a biologic nine amino acid peptide, which is being evaluated for the treatment of breast neoplasms.

                            Brand Name : GLSI-100

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            June 14, 2024

                            Lead Product(s) : GP2 Peptide,GM-CSF

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $2.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP2 Peptide,GM-CSF

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Greenwich LifeSciences Phase III Trial Approved in Five European Countries

                            Details : GLSI-100 (GP2 + GM-CSF) is a biologic peptide of the HER2/neu protein with GM-CSF, stimulating an immune response against HER2/neu cancers, evaluated for HER2/neu positive breast cancer.

                            Brand Name : GLSI-100

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            February 27, 2024

                            Lead Product(s) : GP2 Peptide,GM-CSF

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP2 Peptide,GM-CSF

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in ...

                            Details : The study demonstrated that GLSI-100, an immunotherapy safely elicited a potent immune response, as evidenced by injection site reactions that correlate to and may serve as a complement to immune response data such as DTH.

                            Brand Name : GLSI-100

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 19, 2022

                            Lead Product(s) : GP2 Peptide,GM-CSF

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP2 Peptide,GM-CSF

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

                            Details : With completion of three clinical lots of GP2 for use in Flamingo-01 trial, and in any additional clinical trials run in parallel, Company intends to file additional patent claims surrounding manufacturing of GP2 and the administration of GLSI-100 immuno...

                            Brand Name : GLSI-100

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            March 03, 2022

                            Lead Product(s) : GP2 Peptide,GM-CSF

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP2 Peptide,GM-CSF

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

                            Details : GLSI-100 (GP2 and GM-CSF), immunotherapy to prevent breast cancer Phase III clinical trial critical steps toward study initiation have been completed, including manufacturing, contracting with clinical trial partners, and setting up infrastructure.

                            Brand Name : GLSI-100

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            February 01, 2022

                            Lead Product(s) : GP2 Peptide,GM-CSF

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP2 Peptide,GM CSF

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

                            Details : GP2 immunotherapy generated GP2-specific immune responses, leading to no metastatic breast cancer recurrence in the HER2/neu 3+ population in the Phase IIb clinical trial, thus supporting GP2’s mechanism of action.

                            Brand Name : GP2

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            November 10, 2021

                            Lead Product(s) : GP2 Peptide,GM CSF

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP2 Peptide,GM CSF

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts

                            Details : The broad based immune response suggests the potential for GP2 to treat other HER2/neu 1-3+ expressing cancers. GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy.

                            Brand Name : GP2

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            November 09, 2021

                            Lead Product(s) : GP2 Peptide,GM CSF

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Greenwich LifeSciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP2 Peptide,GM CSF

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments

                            Details : GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center Phase IIb clinical trial, no recurrences were observed after median 5 years of follow-up.

                            Brand Name : GP2

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 09, 2021

                            Lead Product(s) : GP2 Peptide,GM CSF

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Westport Bio

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Westport Bio

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GP2 Peptide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Greenwich LifeSciences

                            Deal Size : $0.2 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates

                            Details : Westport Bio’s coronavirus vaccine program includes up to 7 vaccine candidates which are designed to complement or improve upon the DNA/RNA based coronavirus vaccines that are in advanced Phase III clinical trials or that have recently received EUA fro...

                            Brand Name : GP2

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 15, 2020

                            Lead Product(s) : GP2 Peptide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Greenwich LifeSciences

                            Deal Size : $0.2 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth